Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$21.35

0.165 (0.78%)

, TSRO

TESARO

$99.26

-0.63 (-0.63%)

06:57
10/10/16
10/10
06:57
10/10/16
06:57

TESARO data suggest Myriad test not necessary, says Piper Jaffray

Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.

MYGN

Myriad Genetics

$21.35

0.165 (0.78%)

TSRO

TESARO

$99.26

-0.63 (-0.63%)

  • 10

    Oct

  • 06

    Nov

  • 11

    Jan

MYGN Myriad Genetics
$21.35

0.165 (0.78%)

08/10/16
08/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. SunPower (SPWR) downgraded to Neutral from Overweight at JPMorgan, to Perform from Outperform at Oppenheimer, to Hold from Buy at Deutsche Bank, to Neutral from Buy at Janney Capital, to Neutral from Outperform at Credit Suisse, and to Market Perform from Outperform at Avondale. 2. Noble Corp. (NE) downgraded to Sell from Hold at Argus with analyst David Coleman saying the company is being hurt by declining offshore drilling activity, lower fleet utilization and falling day rates. 3. Wayfair (W) downgraded to Neutral from Buy at Goldman and to Neutral from Buy at BofA/Merrill. 4. Buffalo Wild Wings (BWLD) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro saying shares are fairly valued in the context of below average comp visibility in the near-term and largely discount the benefits of near-term potential activist proposals. 5. Myriad Genetics (MYGN) downgraded to Equal Weight from Overweight at Barclays, to Neutral from Overweight at Piper Jaffray, to Market Perform from Outperform at Wells Fargo, and to Hold from Buy at Gabelli. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/16
SPHN
08/11/16
NO CHANGE
Target $30
SPHN
Overweight
Myriad Genetics price target lowered to $30 from $47 at Stephens
Stephens analyst Drew Jones lowered his price target for Myriad Genetics to $30 from $47 after the company missed Q4 expectations slightly and issued "disappointing" 2017 guide. The analyst sees hereditary cancer as the "primary culprit," with sales turnover blamed for volume weakness. Further, Jones believes the lack of visibility into this weakness has created an overhang that will not be solved with "one decent quarter." He reiterates an Overweight rating on the shares.
08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
TSRO TESARO
$99.26

-0.63 (-0.63%)

10/10/16
SBSH
10/10/16
NO CHANGE
Target $125
SBSH
Buy
Citi sees broad label for TESARO, ups target to $125
Citi analyst Robyn Karnauskas raised her price target for TESARO to $125 from $120 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The stock in pre-market trading is up 4% to $103.10. Niraparib maintenance helps all ovarian cancer patients, making a broad label likely, Karnauskas tells investors in a research note. The analyst keeps a Buy rating on TESARO shares.
10/10/16
BOFA
10/10/16
UPGRADE
BOFA
Buy
TESARO upgraded to Buy from Neutral at BofA/Merrill
10/10/16
BOFA
10/10/16
UPGRADE
Target $123
BOFA
Buy
TESARO upgraded to Buy following NOVA study data at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad upgraded TESARO to Buy and raised its price target to $123 from $97 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Ahmad said the data removes a key overhang of efficacy outside of BRCA mutations and sees a clearer path towards approval and a favorable label.

TODAY'S FREE FLY STORIES

MBLY

Mobileye

$46.12

0.47 (1.03%)

08:03
02/22/17
02/22
08:03
02/22/17
08:03
Recommendations
Mobileye analyst commentary  »

Mobileye deal with BMW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MO

Altria Group

$73.65

0.68 (0.93%)

08:02
02/22/17
02/22
08:02
02/22/17
08:02
Earnings
Altria Group backs FY17 adjusted EPS view $3.26-$3.32, consensus $3.31 »

Altria reaffirms its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:02
02/22/17
02/22
08:02
02/22/17
08:02
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$73.65

0.68 (0.93%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Hot Stocks
Breaking Hot Stocks news story on Altria Group »

Altria Group reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:56
02/22/17
02/22
07:56
02/22/17
07:56
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Restaurant Brands…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

ARGS

Argos Therapeutics

$4.40

-0.3 (-6.38%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Argos Therapeutics »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Apr

GS

Goldman Sachs

$251.76

1.38 (0.55%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Initiation
Goldman Sachs initiated  »

Goldman Sachs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

RDS.A

Royal Dutch Shell

$52.49

0.29 (0.56%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
Royal Dutch Shell to hold a conference call »

EVP of Gas and Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ACRX

AcelRx

$3.15

0.05 (1.61%)

, CBM

Cambrex

$54.90

0.55 (1.01%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

ACRX

AcelRx

$3.15

0.05 (1.61%)

CBM

Cambrex

$54.90

0.55 (1.01%)

CRIS

Curis

$2.66

-0.02 (-0.75%)

ESPR

Esperion

$24.42

-0.58 (-2.32%)

DVAX

Dynavax

$3.95

-0.05 (-1.25%)

FLXN

Flexion

$19.66

0.43 (2.24%)

GILD

Gilead

$69.29

-0.56 (-0.80%)

CURE

Curative Health Services Inc

$33.80

0.45 (1.35%)

PCRX

Pacira

$44.15

0.45 (1.03%)

NVDQ

Novadaq

$6.76

0.17 (2.58%)

AXON

Axovant Sciences

$12.11

-0.03 (-0.25%)

TSRO

TESARO

$190.27

-0.09 (-0.05%)

EGRX

Eagle Pharmaceuticals

$73.59

-0.53 (-0.72%)

LPNT

LifePoint

$65.15

1.25 (1.96%)

PRTA

Prothena

$55.00

-0.22 (-0.40%)

ABEO

Abeona Therapeutics

$5.25

-0.75 (-12.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 02

    Mar

  • 06

    Mar

  • 17

    Mar

  • 21

    Mar

  • 01

    Apr

  • 27

    Apr

  • 30

    Jun

  • 06

    Oct

MS

Morgan Stanley

$46.56

0.41 (0.89%)

07:54
02/22/17
02/22
07:54
02/22/17
07:54
Initiation
Morgan Stanley initiated  »

Morgan Stanley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
02/22/17
02/22
07:53
02/22/17
07:53
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$76.10

2 (2.70%)

07:52
02/22/17
02/22
07:52
02/22/17
07:52
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

SOHO

Sotherly Hotels

$7.04

-0.4 (-5.38%)

07:51
02/22/17
02/22
07:51
02/22/17
07:51
Recommendations
Sotherly Hotels analyst commentary  »

Sotherly Hotels can still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$45.60

-0.02 (-0.04%)

07:49
02/22/17
02/22
07:49
02/22/17
07:49
Initiation
Glaukos initiated  »

Glaukos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DBD

Diebold

$29.70

-0.4 (-1.33%)

07:48
02/22/17
02/22
07:48
02/22/17
07:48
Initiation
Diebold initiated  »

Diebold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FSLR

First Solar

$36.62

1.78 (5.11%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$126.34

1.07 (0.85%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Hot Stocks
Aetna announces $3.3B accelerated share repurchase »

Aetna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Conference/Events
CFA Society of Washington, D.C. to hold a luncheon discussion »

The CFA Society of…

CSCO

Cisco

$34.13

0.39 (1.16%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Cisco analyst commentary  »

Cisco at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

M

Macy's

$32.29

-0.01 (-0.03%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Macy's analyst commentary  »

Macy's risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$111.07

3.84 (3.58%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Initiation
NVIDIA initiated  »

NVIDIA initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

EYEG

EyeGate

$3.70

2.0601 (125.62%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files $3.29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$66.94

1.02 (1.55%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Hot Stocks
Welltower enters into strategic collaboration with Johns Hopkins Medicine »

Welltower announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 01

    Mar

HD

Home Depot

$145.02

2.02 (1.41%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Recommendations
Home Depot analyst commentary  »

Home Depot guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.